Header Logo

Connection

Alan Landay to Lipopolysaccharides

This is a "connection" page, showing publications Alan Landay has written about Lipopolysaccharides.
Connection Strength

0.165
  1. Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis. 2015 Mar 01; 211(5):780-90.
    View in: PubMed
    Score: 0.029
  2. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014 Nov 15; 210(10):1549-54.
    View in: PubMed
    Score: 0.028
  3. Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus. J Infect Dis. 2013 Aug 15; 208(4):679-89.
    View in: PubMed
    Score: 0.026
  4. Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood. 2012 Aug 16; 120(7):1357-66.
    View in: PubMed
    Score: 0.025
  5. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009 Apr 15; 199(8):1177-85.
    View in: PubMed
    Score: 0.020
  6. Effect of mucosal fluid from women with bacterial vaginosis on HIV trans-infection mediated by dendritic cells. Virology. 2009 Mar 01; 385(1):22-7.
    View in: PubMed
    Score: 0.020
  7. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006 Dec; 12(12):1365-71.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.